Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2013, Pages 685-693

  Konieczynska, Malgorzata ^a   Fil, Korneliusz ^a   Bazanek, Marta ^a   Undas, Anetta ^b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Diabetes; Fibrin clot; Fibrinolysis; Glycaemic control; Thrombin

Indexed keywords

ANTIPLASMIN; BIGUANIDE; FIBRINOGEN; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOT PERMEABILITY; BLOOD CLOTTING; CALIBRATED AUTOMATED THROMBOGRAPHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; EUGLOBULIN LYSIS TEST; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOFIBRINOGENEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERMEABILITY; PRIORITY JOURNAL; RETINOPATHY; SCANNING ELECTRON MICROSCOPY; TURBIDITY; BLOOD; FIBRINOLYSIS; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; TIME;

AGED; BLOOD COAGULATION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TIME FACTORS;

EID: 84897485898     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-07-0566     Document Type: Article

References (35)

1. Stratmann B, Tschoepe D. Atherogenesis and atherothrombosis-focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009; 23: 291-303.
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 350: 229-234.
3. Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 2011; 121: 310-318.
4. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
5. Undas A, Wiek I, Stepien E, et al. Hyperglycaemia is associated with enhanced thrombin formation, platelet activation and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 2008; 31: 1590-1595.
6. Undas A, Szuldrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-558.
7. Rooth E, Wallen NH, Blombäck M, et al. Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischaemic stroke. Thromb Res 2011; 127: 51-56.
8. Undas A, Slowik A, Wolkow P, et al. Fibrin clot properties in acute ischaemic stroke: relation to neurological deficit. Thromb Res 2010; 125: 357-361.
9. Undas A, Nowakowski T, Ciesla-Dul M, et al. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011; 215: 481-486.
10. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
11. Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
12. Jorneskog G, Egberg N, Fagrell B, et al. Altered properties of fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
13. Dunn E, Philippou H, Ariëns RAS, et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
14. Dunn E, Ariëns RAS, Grant PJ. The influence of type 2 diabetes on clot structure and function. Diabetologia 2005; 48: 1198-1206.
15. Alzahrani SH, Aijan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7: 260-273.
16. Undas A, Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolism diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
17. Pieters M, Covic N, van der Westhuizen FH, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes. A purified fibrinogen model. Thromb Haemost 2008; 99: 691-700.
18. Jorneskog G, Hansson LO, Wallen NH, et al. Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1: 1195-1201.
19. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828.
20. Bloomgarten ZT. Diabetes and cardiovascular disease. Diabetes Care 2011; 31: e24-e30.
21. Ceriello A, Ihnat MA, Thorpe JE. The "Metabolic Memory": Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009, 94: 410-415.
22. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care 2010; 33: 2285-2293.
23. Stepien E, Plicner D, Branicka A, et al. Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Med Wew 2007; 117: 297-305.
24. Lisman T, Leebeek FWG, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
25. Williams S, Fatah K, Ivert T, et al. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 6: 718-725.
26. Undas A, Celinska-Lowenhoff M, Lowenhoff T, et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
27. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
28. Meltzer ME, Lisman T, Doggen CJ, et al. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5: e97.
29. Pankiw-Bembenek O, Zalewski J, Goralczyk T, et al. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107: 513-520.
30. Siegerink B, Meltzer ME, de Groot PG, et al. Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study. Br J Haematol 2012; 156: 252-258.
31. Bochenek M, Zalewski J, Sadowski J, et al. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis 2013; 35: 264-270.
32. Wannamethee SG, Sattar N, Rumley A, et al. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 2008: 31: 995-1000.
33. Schneider DJ, Sobel BE. PAI-1 and diabetes. A journey from the bench to the bedside. Diabetes Care 2012; 35: 1961-1967.
34. Al Dieri R, de Laat B, Hemker HC. Thrombin generation: What have we learned? Blood Rev 2012; 26: 197-203.
35. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-390.